Clinical Trial Update: Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics [Phase 1, Phase 2]

View source ↗

Summary

The document reports the completion of a Phase 1/2 pharmacokinetic study of Epinephrine Inhalation Aerosol USP delivered via an HFA-MDI for asthma-related bronc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Epinephrine Inhalation Aerosol USP (HFA-MDI) (epinephrine)

Snippet

Sponsor: Amphastar Pharmaceuticals, Inc. | Conditions: Asthma, Bronchospasm | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-10-24